Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344780
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Abemaciclib Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-28
First Submit QC Date:
March 28 2024
Study First Post Date:
2024-04-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-01
Last Update Post Date:
2024-04-03
Last Update Post Date Type:
ACTUAL